Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
赞助:
Sanofi Pasteur, a Sanofi Company
合作者:
信息的提供 (责任方):
，
| 追踪信息 | |||
|---|---|---|---|
| 首次提交日期 ICMJE | October 4, 2018 | ||
| 首次发布日期e ICMJE | October 5, 2018 | ||
| 最后更新发布日期 | October 5, 2018 | ||
| 预计研究开始日期 ICMJE | September 18, 2018 | ||
| 预计主要完成日期 | August 2019 (主要结果测量的最终数据收集日期) | ||
| 目前主要观察指标 ICMJE |
Number of participants reporting solicited injection site reactions or systemic reactions[ Time Frame: Within 7 days after any injection ] Injection site reactions: tenderness/pain, erythema, swelling, induration and bruising. Systemic reactions for participants < 36 months: fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability; 3 to 17 years: fever, headache, malaise, myalgia, and shivering Geometric mean titers (GMTs) of influenza vaccine antibodies[ Time Frame: Day 28 after each injection ] Antibody titers are measured by HAI and expressed as GMTs Influenza vaccine antibody titer ratio[ Time Frame: Day 28 after each injection ] Ratio of titers measured by HAI on Day 28/Day 0 for all participants and Day 56/Day 0 for participants receiving 2 injections Number of participants with seroconversion[ Time Frame: Day 28 after each injection ] Antibody titers are measured by HAI. Seroconversion is defined as titer < 10 [1/dilution {dil}] at Day 0 and post-injection titer ≥ 40 [1/dil] at Day 28, or titer ≥ 10 [1/dil] at Day 0 and a ≥ 4-fold increase in titer [1/dil] at Day 28 Number of participants with titers ≥ 40 (1/dil)[ Time Frame: Day 28 after each injection ] Antibody titers are measured by HAI Neutralization test (NT) titers of influenza vaccine antibodies[ Time Frame: Day 28 after each injection ] Antibody titers are measured by virus SN method and expressed as NT titers Influenza vaccine antibody NT titer ratio[ Time Frame: Day 28 after each injection ] Ratio of titers measured by virus SN method on Day 28/Day 0 for all participants and Day 56/Day 0 for participants receiving 2 injections Participants with influenza vaccine antibody NT titers above pre-defined thresholds[ Time Frame: Day 28 after each injection ] Antibody titers are measured by virus SN method Fold-increase in influenza vaccine antibody NT titer[ Time Frame: Day 28 after each injection ] Antibody titers are measured by virus SN method. The increase post/pre-injection ≥2 and ≥ 4 is assessed |
||
| 原始主要观察测量 ICMJE | 与当前相同 | ||
| 目前的二级观察 ICMJE |
|
||
| 描述性信息 | |||
| 简略标题 ICMJE | Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age | ||
| 正式标题 ICMJE | Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age | ||
| 简要概况 | The objectives of this study are: - To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including adverse events of special interest throughout the study - To describe the antibody response induced by each dosage of QIV-HD used in the study compared with unadjuvanted standard-dose quadrivalent influenza vaccine (QIV-SD) by hemagglutination inhibition (HAI) - To describe the antibody response induced by each dosage of QIV-HD used in the study compared with unadjuvanted QIV-SD by virus seroneutralization (SN) measurement methods - To describe the antibody response induced by the highest acceptable dosage of QIV-HD compared with adjuvanted trivalent influenza vaccine (TIV) by HAI and virus SN measurement methods |
||
| 详细说明 | Study duration per participant will be approximately 180 days for participants receiving one dose of vaccine and 208 days for participants receiving two doses of vaccine | ||
| 研究类型 ICMJE | Interventional | ||
| 研究阶段 | Phase 2 | ||
| 研究设计 ICMJE | 分配: Randomized 干预模型: Sequential Assignment 干预模型描述: The study will be divided into 13 groups and will enroll in 4 stages. The study will use a stepwise age de-escalation and dose ascension design for children 6 months to < 5 years of age. 盲法: Interventional 盲法描述:Modified double-blind: the participant's parent / legally acceptable representative, the Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator will administer the appropriate vaccine but will not be involved in safety data collection. 主要目的: Prevention |
||
| 适用条件 ICMJE | |||
| 干预项目 ICMJE |
|
||
| 研究工具 |
|
||
| 招募信息 | |||
| 招募状态 ICMJE | Recruiting | ||
| 预计入组 ICMJE |
700 | ||
| 原始预计入组 ICMJE | 与当前相同 | ||
| 预计研究完成日期 | August 2019 | ||
| 预计主要完成日期 | August 2019 (主要结果测量的最终数据收集日期) | ||
| 合格标准 ICMJE | Inclusion criteria : - Aged 6 months to 17 years on the day of inclusion - Assent form has been signed and dated by the subject (7 to 17 years of age) and informed consent form has been signed and dated by the parent(s) or guardian(s) and by an independent witness, if required by local regulations - Subject / and subject and parent / guardian are able to attend all scheduled visits and to comply with all study procedures - For subjects aged < 24 months: Born at full term of pregnancy (≥ 37 weeks) and/or with a birth weight ≥ 2.5 kg Exclusion criteria: - Subject is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, a female must be pre-menarche - Participation at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure - Receipt of any vaccine in the 30 days preceding the first study vaccination, or planned receipt of any vaccine before Visit 3 for subjects receiving 1 dose of influenza vaccine or Visit 5 for subjects receiving 2 doses of influenza vaccine - For previously influenza vaccinated subjects: Previous vaccination against influenza in the preceding 6 months with either the study vaccine or another vaccine - For previously influenza unvaccinated subjects: Any influenza vaccination (from birth to the day of inclusion) with either the study vaccine or another influenza vaccine - For previously influenza unvaccinated subjects: Any previous laboratory confirmed influenza infection (from birth to the day of inclusion) - Receipt of immune globulins, blood or blood-derived products in the past 3 months - Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances - Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on Investigator's judgement - Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily - Current alcohol abuse or drug addiction - Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion - Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0 C [≥ 100.4 F]). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided - Identified as an immediate family member (ie, spouse, natural or adopted child, grandchild, nephew, or niece) of the Investigator or employee with direct involvement in the proposed study - Personal history of GBS - Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine - Personal history of clinically significant development delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder - Known seropositivity for hepatitis B or hepatitis C The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. | ||
| 性别 |
|
||
| 年龄 | 最小年龄：6 Months ，最大年龄：17 Years | ||
| 接受健康的志愿者 | 没有 | ||
| 可入组国家 ICMJE | United States | ||
| 管理信息 | 数据检测委员会 | No | |
| 研究涉及美国FDA监管的产品 |
研究美国FDA监管的药品: Yes 研究涉及美国FDA监管的设备产品: No |
||
| IPD 共享声明 |
|
||
| 责任方 | ， | ||
| 研究赞助商 ICMJE | Sanofi Pasteur, a Sanofi Company | ||
| 合作者 ICMJE | |||
| 研究员 ICMJE |
|
||
| PRS 账户 | |||
| 验证日期 | October 2018 | ||
|
ICMJE 国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素 |
|||
请使用微信扫码报名
京公网安备 11010102003638号